Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis Group
2023-01-01
|
| Cyfres: | Human Vaccines & Immunotherapeutics |
| Pynciau: | |
| Mynediad Ar-lein: | http://dx.doi.org/10.1080/21645515.2023.2207438 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|